Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Products In Brief: Salonpas gel, algal protein in CleanSeries, Kemin eye health line, Merck supplies Solgar folate

This article was originally published in The Tan Sheet

Executive Summary

Salonpas gel targets pain precisely; Twinlab adds algal protein to CleanSeries; ZeaONE expands Kemin eye health line; Merck supplies Solgar folate; Cyvex offers fish-derived protein powder; NeuroScience calming products now dissolvable; Organix-South soothes with neem rub.

You may also be interested in...



In Brief

FDA approves OTC HIV test; Good Herbs disclaimer does not cancel drug claims; American Herbal Pharmacopoeia releases blue cohosh monograph; salmonella triggers Standard Process supplement recall; Kemin, Ball see zeaxanthin partnership bloom; more In Brief.

Glenmark’s Ryaltris Set To Hit Canadian Market

Health Canada approves Ryaltris for allergic rhinitis, opening up yet another major market for Glenmark’s branded specialty medicine. Bausch Health will sell the drug in Canada.

Evusheld: UK Urged To Use RWD To Give Clinically Vulnerable Early Access To COVID-19 Treatment

A full appraisal by the UK cost watchdog is not the only way to gauge the safety and effectiveness of Evusheld, argues the independent Drug Safety Research Unit in response to the government’s decision not to buy the licensed COVID-19 drug because of insufficient data on protection. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel